Zobrazeno 1 - 10
of 273
pro vyhledávání: '"Carmen J, Allegra"'
Autor:
Samuel A. Jacobs, Ying Wang, Jame Abraham, Huichen Feng, Alberto J. Montero, Corey Lipchik, Melanie Finnigan, Rachel C. Jankowitz, Mohamad A. Salkeni, Sai K. Maley, Shannon L. Puhalla, Fanny Piette, Katie Quinn, Kyle Chang, Rebecca J. Nagy, Carmen J. Allegra, Kelly Vehec, Norman Wolmark, Peter C. Lucas, Ashok Srinivasan, Katherine L. Pogue-Geile
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-13 (2024)
Abstract Background We previously reported our phase Ib trial, testing the safety, tolerability, and efficacy of T-DM1 + neratinib in HER2-positive metastatic breast cancer patients. Patients with ERBB2 amplification in ctDNA had deeper and more dura
Externí odkaz:
https://doaj.org/article/c30874be81f04b78be67858f937fdb82
Autor:
Samuel A. Jacobs, Ying Wang, Jame Abraham, Huichen Feng, Alberto J. Montero, Corey Lipchik, Melanie Finnigan, Rachel C. Jankowitz, Mohamad A. Salkeni, Sai K. Maley, Shannon L. Puhalla, Fanny Piette, Katie Quinn, Kyle Chang, Rebecca J. Nagy, Carmen J. Allegra, Kelly Vehec, Norman Wolmark, Peter C. Lucas, Ashok Srinivasan, Katherine L. Pogue-Geile
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/4cc93b26e3c04e74a206892c9a22fe0a
Autor:
Sajid Khan, Janet Wiegand, Peiyi Zhang, Wanyi Hu, Dinesh Thummuri, Vivekananda Budamagunta, Nan Hua, Lingtao Jin, Carmen J. Allegra, Scott E. Kopetz, Maria Zajac-Kaye, Frederic J. Kaye, Guangrong Zheng, Daohong Zhou
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-5 (2022)
Abstract KRAS mutations are the most common oncogenic drivers. Sotorasib (AMG510), a covalent inhibitor of KRASG12C, was recently approved for the treatment of KRASG12C-mutated non-small cell lung cancer (NSCLC). However, the efficacy of sotorasib an
Externí odkaz:
https://doaj.org/article/776b73003bc44789a62395d3ecb0ff21
Autor:
Samuel A. Jacobs, André Robidoux, Jame Abraham, José Manuel Pérez-Garcia, Nicla La Verde, James M. Orcutt, Marina E. Cazzaniga, Fanny Piette, Silvia Antolín, Elena Aguirre, Javier Cortes, Antonio Llombart-Cussac, Serena Di Cosimo, Rim S. Kim, Huichen Feng, Corey Lipchik, Peter C. Lucas, Ashok Srinivasan, Ying Wang, Nan Song, Patrick G. Gavin, April D. Balousek, Soonmyung Paik, Carmen J. Allegra, Norman Wolmark, Katherine L. Pogue-Geile
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-11 (2019)
Abstract Purpose The primary aim of NSABP FB-7 was to determine the pathologic complete response (pCR) rate in locally advanced HER2-positive (HER2+) breast cancer patients treated with neoadjuvant trastuzumab or neratinib or the combination and week
Externí odkaz:
https://doaj.org/article/8c6fc04f4e924176a82cabe4e3ccf226
Autor:
Brian H Ramnaraign, Ji-Hyun Lee, Azka Ali, Sherise C Rogers, Jesus C Fabregas, Ryan M Thomas, Carmen J Allegra, Ilyas Sahin, David L DeRemer, Thomas J George, Jonathan A Chatzkel
Publikováno v:
Future Oncology. 18:3815-3822
Immune checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance and the inhibition of this interaction is an effective treatment strategy for numerous malignancies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::befb38bcf4f60c643c910a11decc276d
https://doi.org/10.2217/fon-2022-0392
https://doi.org/10.2217/fon-2022-0392
Autor:
Samuel A. Jacobs, André Robidoux, Jame Abraham, José Manuel Pérez-Garcia, Nicla La Verde, James M. Orcutt, Marina E. Cazzaniga, Fanny Piette, Silvia Antolín, Elena Aguirre, Javier Cortes, Antonio Llombart-Cussac, Serena Di Cosimo, Rim S. Kim, Huichen Feng, Corey Lipchik, Peter C. Lucas, Ashok Srinivasan, Ying Wang, Nan Song, Patrick G. Gavin, April D. Balousek, Soonmyung Paik, Carmen J. Allegra, Norman Wolmark, Katherine L. Pogue-Geile
Publikováno v:
Breast Cancer Research, Vol 22, Iss 1, Pp 1-2 (2020)
After the publication of this work [1] the authors have reported that in Table 3 The letter “T” in columns 5 and 7 should not be there.
Externí odkaz:
https://doaj.org/article/1224ca9686ff4ace8904fdb0d7ec7ea5
Autor:
Ashok Srinivasan, Carmen J. Allegra, Peter C. Lucas, Norman Wolmark, Jan H. Beumer, Brian F. Kiesel, Melanie Finnigan, Ying Wang, Huichen Feng, Corey Lipchik, Patrick G. Gavin, Rim S. Kim, Katherine L. Pogue-Geile, Fanny Piette, Ashwin R. Sama, Ding Wang, Philip J. Stella, James L. Wade, Thomas J. George, James J. Lee, Samuel A. Jacobs
Purpose:In metastatic colorectal cancer (mCRC), HER2 (ERBB2) gene amplification is implicated in anti-EGFR therapy resistance. We sought to determine the recommended phase II dose (RP2D) and efficacy of neratinib, a pan-ERBB kinase inhibitor, combine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1245c78b3812c0cf88ea25d3e6a63da1
https://doi.org/10.1158/1078-0432.c.6530607.v1
https://doi.org/10.1158/1078-0432.c.6530607.v1
Autor:
Ashok Srinivasan, Carmen J. Allegra, Peter C. Lucas, Norman Wolmark, Jan H. Beumer, Brian F. Kiesel, Melanie Finnigan, Ying Wang, Huichen Feng, Corey Lipchik, Patrick G. Gavin, Rim S. Kim, Katherine L. Pogue-Geile, Fanny Piette, Ashwin R. Sama, Ding Wang, Philip J. Stella, James L. Wade, Thomas J. George, James J. Lee, Samuel A. Jacobs
Supplemental Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::183c50348f78b182ac2d0dfe83ec7809
https://doi.org/10.1158/1078-0432.22481040.v1
https://doi.org/10.1158/1078-0432.22481040.v1
Autor:
Ashok Srinivasan, Carmen J. Allegra, Peter C. Lucas, Norman Wolmark, Jan H. Beumer, Brian F. Kiesel, Melanie Finnigan, Ying Wang, Huichen Feng, Corey Lipchik, Patrick G. Gavin, Rim S. Kim, Katherine L. Pogue-Geile, Fanny Piette, Ashwin R. Sama, Ding Wang, Philip J. Stella, James L. Wade, Thomas J. George, James J. Lee, Samuel A. Jacobs
Figure SF3 Comparisons of the expression of the NRG family of ERBB ligands, at the RNA level, between post-anti-EGFR metastatic biopsies collected upon enrollment into FC-7, and post-neratinib residual tumor tissue samples.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76dd9652d0b387d9b195e9248619d2c0
https://doi.org/10.1158/1078-0432.22481046
https://doi.org/10.1158/1078-0432.22481046
Publikováno v:
J Natl Cancer Inst
Recently developed clinical-benefit outcome scales by the European Society for Medical Oncology and the American Society of Clinical Oncology allow standardized objective evaluation of outcomes of randomized clinical trials. However, incorporation of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bb198f644dd728e6714b3240093f8ec
https://doi.org/10.1093/jnci/djac099
https://doi.org/10.1093/jnci/djac099